% | $
Quotes you view appear here for quick access.

Nymox Pharmaceutical Corporation Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • tansexygrl tansexygrl Apr 22, 2000 6:40 PM Flag

    Insider buying?

    Novartis AG Gets FDA OK To Market Exelon
    Jones Newswires
    EAST HANOVER, N.J. -- Novartis AG's
    (Z.NOV) Novartis Pharmaceuticals Corp. received Food and
    Drug Administration approval to market Exelon, a
    cholinesterase inhibitor for the treatment of patients with mild
    to moderate Alzheimer's disease.

    In a press
    release Friday, the company said Exelon is now cleared
    for marketing in nearly 70 countries.

    Platt; Dow Jones Newswires; 201-938-5400

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • The market potential for Alzheimer's diagnostics
      (screening and monitoring therapy) is estimated to be
      $6-800M in the US alone. Quite frankly, I didn't acquire
      this stock with the drug therapy in mind...rather to
      play the diagnostic products. Unless NYMX gets a BIG
      Pharma partner to develop any compound, they should
      stick to the diagnostic side. The Serex thing gives
      them a number of new and exciting options there. Hey,
      just one investors opinion...p.s. love your screen

3.28-0.02(-0.61%)Oct 21 4:00 PMEDT